GlassScriptPhysician profile
Ivan M Dankanich
NPI 1295182269
$1,633.90
in general payments reported to CMS, 2019-2025
19 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $488 · 2023: $298 · 2024: $367 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $411.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $194.78 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $177.87 | 2023-2025 | |
| Glaxosmithkline, LLC. | $175.85 | 2022-2024 | Trelegy Ellipta |
| Amgen INC. | $107.20 | 2022-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $106.61 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.93 | 2022-2023 | |
| Esperion Therapeutics, INC. | $74.80 | 2023-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $54.34 | 2022-2024 | |
| Madrigal Pharmaceuticals | $33.00 | 2024 | Resmetirom |
| Astrazeneca Pharmaceuticals LP | $28.20 | 2024-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $27.11 | 2025 | Veozah |
| Abiomed | $25.49 | 2024 | Impella |
| Corcept Therapeutics | $23.02 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $21.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.52 | 2022 | |
| Dexcom, INC. | $16.37 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.69 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Dankanich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.